Sarepta Therapeutics Inc
SRPT
Market Cap$11.76B
Close$
$153.22
18% upside
Current Fair Value
18% upsideUndervalued by 18% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.76 Billion |
|---|---|
| Enterprise Value | $11.61 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.18 |
| Beta | 0.6 |
| Outstanding Shares | 94,523,766 |
| Avg 30 Day Volume | 1,387,666 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 696.19 |
|---|---|
| PEG | -650.71 |
| Price to Sales | 9.28 |
| Price to Book Ratio | 12.99 |
| Enterprise Value to Revenue | 8.27 |
| Enterprise Value to EBIT | -122.45 |
| Enterprise Value to Net Income | 687 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 1.29 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Sarepta Therapeutics Inc
CEO: Douglas Ingram Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...